International
BBMRI-ERIC is a European research infrastructure for biobanking. We bring together all the main players from the biobanking field – researchers, biobankers, industry, and patients – to boost biomedical research. To that end, we offer quality management services, support with ethical, legal and societal issues, and a number of online tools and software solutions. Ultimately, our goal is to make new treatments possible.
View this resource Bookmark this resourceThis article is a review of the main concepts about In silico modeling of diseases. Examples and applications of In silico modeling for some important categories of diseases (such as for cancers, infectious diseases, and neuronal diseases) are also given.
View this resource Bookmark this resourceThis website provides In silico modeling tools to measure key aspects affecting the performance of nanomedicines release. It offers physiologically-based biopharmaceutics (PBB) modeling with the aims to support the development of the novel in vitro methods.
View this resource Bookmark this resource
In Silico Model in Toxicology and Risk Assessment
Published by Frontiers Media
In silicophysiologically-based kinetic and dynamic modelQSAR modelThis article aims to address the latest developments in the area of In silico modelling and New approach methodologies (NAMs) including physiologically-based kinetic and dynamic (PBK-D) model, In silico model for the prediction of toxicological such as QSAR model and machine learning algorithms, the use of quantitative adverse outcome pathways for hazard characterisation of chemicals to cite but a few
View this resource Bookmark this resource
In silico Methods for Drug Design and Discovery
Published by Computers in Biology and Medicine
In sillicomethodstoolsIn this review,is briefly introduced computational drug discovery strategies and outline up-to-date tools to perform the strategies as well as available knowledge bases for those who develop their own computational model.
View this resource Bookmark this resource
Development of new effective therapies for rare diseases
Published by European Commission (EC)
GrantRare DiseaseThis topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to some of the following expected outcomes:
Researchers and developers make the best use of the state-of-the-art knowledge and resources for a fast and effective development of new therapies for rare diseases.
Researchers and developers increase the development success rate of therapies for rare diseases by employing robust preclinical models, methods, technologies, validated biomarkers, reliable patient reported outcomes and/or innovative clinical trials designs.
Developers and regulators move faster towards market approval of new therapies for rare diseases (with currently no approved treatment option) due to an increased number of interventions successfully tested in late stages of clinical development.
Healthcare professionals and people living with a rare disease get access to new therapeutic interventions and/or orphan medicinal products.
Research Grant for Rett Syndrome
Published by International Rett Syndrome Foundation
GrantRett SyndromeIRSF believes that research into a variety of Rett and Rett-related topics is necessary to create treatments and eventual cures for every individual living with Rett syndrome. We proudly invest in such research at every stage: from basic science that can change the way we think about MeCP2 to clinical research that directly impacts potential treatments. We also help connect Rett researchers with external funding opportunities.
View this resource Bookmark this resource
INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE
E6(R2)
Published by International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)
Internatonal Council for Harmonisation (ICH)Regulatory AuthoritiesThe International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) brings together the medicines regulatory authorities and pharmaceutical industry around the world.
View this resource Bookmark this resource
Phenotypic screens as a renewed approach for drug discovery
Published by Drug Discov Today.
Drug RepurposingHit IdentificationPhenotypic Screeningin this article reviews the Phenotypic Screening approach and compares its success rate with all others methods used in leads discovery.
View this resource Bookmark this resource